Programmable Periodicity of Quantum Dot Arrays with DNA Origami Nanotubes by Bui, Hieu et al.
Boise State University
ScholarWorks
Materials Science and Engineering Faculty
Publications and Presentations Department of Materials Science and Engineering
8-3-2010
Programmable Periodicity of Quantum Dot Arrays
with DNA Origami Nanotubes
Hieu Bui
Boise State University
Craig Onodera
Boise State University
Carson Kidwell
Boise State University
YerPeng Tan
Boise State University
Elton Graugnard
Boise State University
See next page for additional authors
This document was originally published by American Chemical Society in Nano Letters. Copyright restrictions may apply. DOI: 10.1021/nl101079u
Authors
Hieu Bui, Craig Onodera, Carson Kidwell, YerPeng Tan, Elton Graugnard, Wan Kuang, Jeunghoon Lee,
William B. Knowlton, Bernard Yurke, and William L. Hughes
This article is available at ScholarWorks: http://scholarworks.boisestate.edu/mse_facpubs/15
Programmable Periodicity of Quantum Dot
Arrays with DNA Origami Nanotubes
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ABSTRACT To fabricate quantum dot arrays with programmable periodicity, functionalized DNA origami nanotubes were developed.
Selected DNA staple strands were biotin-labeled to form periodic binding sites for streptavidin-conjugated quantum dots. Successful
formation of arrays with periods of 43 and 71 nm demonstrates precise, programmable, large-scale nanoparticle patterning; however,
limitations in array periodicity were also observed. Statistical analysis of AFM images revealed evidence for steric hindrance or site
bridging that limited the minimum array periodicity.
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The ability to precisely pattern nanoparticles is es-sential for realizing the potential of nanoelectronicand nanoplasmonic devices.1-3 Over the past de-
cade, DNA oligonucleotides have been programmed to
aggregate,4,5 crystallize,6,7 and self-assemble into spatially
discrete assemblies8-13 and linear arrays.14-16 DNA nano-
technology offers a compelling approach toward program-
mable nanoparticle patterning.17-20 By implementing basic
design rules, DNA can be used to form complex nanostruc-
tures using the methods of either tiled DNA motifs or DNA
origami.21-27 When functionalized, these nanostructures
can serve as two-dimensional28-36 and three-dimensional37
nanoparticle scaffolds. Several groups have reported suc-
cessful attachment of semiconductor quantum dots (QDs)
to functionalized DNA.10,33,38 Sharma et al. recently reported
the fabrication of periodic QD arrays formed by tiling DNA
motifs.33 While tiling methods have the ability to create
highly ordered complex arrays, they tend to create continu-
ous sheets; the boundaries of which are not well controlled.
Presented here is a method of fabricating nanoparticle
arrays with controlled periodicity using three-dimensional,
six-helix DNA origami nanotubes. DNA origami nanotubes
of predetermined dimensions were used to precisely arrange
nanoparticles by incorporating binding sites along the axis
of the nanotube using biotin-labeled staple strands. The
unique sequence of each staple strand permits precise
spatial control and modular design of periodic or aperiodic
binding sites. The three-dimensional DNA origami nano-
tubes provide a rigid structure for nanoparticle attachment
in solution. Additionally, the extension of the DNA nano-
tubes into networks via dimerization, polymerization, or
branching offers controlled fabrication of more complex
nanoparticle structures.
The DNA origami nanotubes used in this research were
designed using the principles reported by Mathieu et al.39
and Douglas et al.40 where the single-stranded M13mp18
DNA molecule was folded into a six-helix nanotube bundle
using the DNA origami method developed by Rothemund.25
The design reported here uses 170 unique staple strands to
fold the single-stranded M13mp18 scaffold, resulting in DNA
nanotubes with blunt ends that do not dimerize. The nano-
tube design is illustrated and described in detail in the
Supporting Information S1. Staple strands include 9 strands
with 69 nucleotides, 9 strands with 35 nucleotides, and 152
strands with 42 nucleotides (see Supporting Information S2).
The DNA nanotubes were designed to be 412 nm in length
and 6 nm in diameter. To incorporate nanoparticle binding
sites, prior to nanotube synthesis, selected staple strands
were extended with a 2.2 nm tether consisting of 5 thymine
nucleotides and modified with biotin at the 3′ end. The
resulting DNA nanotubes possessed precisely spaced biotin
binding sites for controlled positioning of streptavidin-
conjugated nanoparticles along the length of the nanotube
(see Supporting Information S3).
To test controlled nanoparticle patterning, four distinct
DNA nanotubes were synthesized with evenly spaced bind-
ing sites designed to attach 5, 9, 15, or 29 streptavidin-
conjugated nanoparticles to form arrays with periodicities
of 71, 43, 29, or 14 nm, respectively. The biotin-labeled DNA
nanotubes were designed by functionalizing the appropriate
staple strands, as described above. The nanotubes were
synthesized by combining M13mp18 viral DNA (New En-
gland Biolabs) with unmodified and biotin-labeled staple
strands (Integrated DNA Technologies) in a molar ratio of
1:10:10 in a solution of 1 × TAE, Mg2+ (40 mM tris, 20 mM
acetic acid, 2 mM ethylenediaminetetracetic acid (EDTA),
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and 12.5 mM magnesium acetate; pH 8.0). TAE, magnesium
acetate tetrahydrate, and laboratory grade water (Milli-Q
Water, Millipore) were purchased from Sigma Aldrich. All
DNA strands were used without further purification. To form
nanotubes, the DNA solution was thermally annealed at 90
°C for 20 min, then cooled to 20 °C at ∼1 °C per minute
using a thermal cycler (Mastercycler, Eppendorf). After the
nanotubes were synthesized, the solution was centrifuged
using a centrifugal filter (100 000 molecular weight cut off)
at 500 g for 15 min to remove excess staple strands and
small, unbound DNA fragments.
Successful formation of biotin-labeled DNA nanotubes
was confirmed via atomic force microscopy (AFM). During
sample preparation, 5 µL of DNA nanotube solution was
dispersed onto freshly cleaved V-4 grade mica with 20 µL
of 1 × TAE, Mg2+ buffer and allowed to adsorb onto the
surface for 5 min. Then, the surface was washed with Milli-Q
water and dried with compressed air. Imaging of function-
alized nanotubes was performed using AFM (Multimode
Picoforce with a Nanoscope IV controller, Veeco Metrology)
under ambient conditions in AC mode using silicon cantilever-
based tips (PPP-NCH, Nanosensors). Cantilevers had a nomi-
nal spring constant of 42 N/m with a range of 10-130 N/m.
To validate the linearity, stability, and accuracy of the
piezoelectric scanner, the AFM was calibrated using (1) a
surface topography reference (STR) with precision fabricated
silicon dioxide rectangular features (VLSI Standards), and (2)
the atomic step height of freshly cleaved, ZYH grade, highly
ordered pyrolytic graphite (HOPG, Veeco Metrology) (see
Supporting Information S4).
Figure 1 shows DNA origami nanotubes with nine biotin
binding sites as synthesized (a-e), after functionalization
with streptavidin (f-j), and after functionalization with
streptavidin-conjugated quantum dots (k-o). Figure 1a il-
lustrates the biotin-labeled nanotube structure, while panels
b and c show low- and high-magnification AFM height
images, respectively. The dashed line in panel c indicates
the location of the cross-sectional height profile in panel d.
From this profile, a nanotube height of ∼2.6 nm is mea-
sured. When measured under various imaging conditions,
the mean nanotube height ranged from 3.5 ( 0.1 to 1.7 (
0.4 nm (see Supporting Information S5). The axial profile
shown in panel e emphasizes relative height variations along
the nanotube length (see Supporting Information S6). The
mean nanotube length was measured to be 436 ( 14 nm
from 100 samples and was independent of the imaging
conditions. The DNA origami nanotubes were designed to
have a circular cross-section equivalent to 3 double helices
(i.e., 6 nm)39 with an expected length of 412 nm. While the
nanotube length is in agreement with the expected value,
the height is less than the expected diameter. According to
Douglas et al., the diameter of DNA nanotubes with six
helices was ∼7( 2 nm using transmission electron micros-
copy (TEM).40 Sources of deviation may include the nano-
tube collapsing onto the mica surface because of surface van
der Waals forces,41,42 capillary effects encountered when
imaging in ambient conditions,41 and compressive forces
during AFM imaging43-45 (see Supporting Information S5).
For example, reduced AFM height profiles for soft biological
samples have been reported in multiple studies.41,46,47
Once biotin-labeled DNA nanotubes were verified via
AFM, the accessibility and reactivity of the biotin attachment
sites were tested by combining a 1 nM solution of biotin-
labeled nanotubes with pure, lyophilized streptavidin pur-
chased from Sigma Aldrich that was resuspended in Milli-Q
water at 200 nM. The components were allowed to react for
2 h at room temperature. The reacted nanotubes were
dispersed onto a freshly cleaved mica surface and dried as
described above. Figure 1f illustrates the biotin-labeled DNA
nanotubes with attached streptavidin. The successful attach-
ment of nine streptavidin molecules is clearly observed by
comparison of the high-magnification AFM images without
streptavidin in panel c and with streptavidin in panel h. The
cross-sectional profile in panel i, obtained at an apparent
streptavidin site, reveals a height increase of ∼0.5 nm
relative to the nanotube shown in panel d. The axial profile
in panel j clearly displays nine peaks with a periodicity of
45 nm, very close to the expected value of 43 nm.
While the measured height increase at a streptavidin site
was ∼0.5 nm, the mean height of free streptavidin, dis-
persed onto freshly cleaved mica, was measured to range
from 2.3 ( 0.5 to 0.7 ( 0.2 nm under various imaging
conditions (see Supporting Information S5). Although X-ray
analysis of dehydrated streptavidin crystals indicated a
thickness of 4.6 nm,48-51 Weisenhorn et al. imaged strepta-
vidin under different AFM contact forces and demonstrated
that the maximum height varied between 1.12, 0.65, and
0.25 nm at 30, 60, and 150 pN, respectively.44 Thus, the
streptavidin heights measured here are consistent with
previous studies.
CdSe/ZnS core/shell streptavidin-conjugated quantum
dots (Qdot 585, Invitrogen), hereafter referred to as quantum
dots, with an average diameter of 15-20 nm were chosen
to test nanoparticle attachment. To ensure a high attachment
yield, a 1 nM solution of functionalized DNA nanotubes was
combined at room temperature with a 200 nM solution of
quantum dots for 2 h. The reacted DNA nanotubes with
attached quantum dots were dispersed onto a mica surface
and dried as described above. Figure 1k illustrates the
attachment of the quantum dots to the biotin-labeled DNA
nanotubes. Figure 1l,m respectively shows low- and high-
magnification AFM height images of the DNA nanotubes
with attached quantum dots. When compared to panels c
and h, quantum dots attach to biotin-labeled DNA nanotubes
with the same periodic spacing. Additionally, the cross-
sectional profile across an apparent quantum dot in panel n
yields a height of 5.5 nm, nearly twice the measured height
of the nanotube with no attached particles. The mean height
of free quantum dots, dispersed onto freshly cleaved mica,
was measured to range from 5.5 ( 0.6 to 4.7 ( 0.7 nm
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under various imaging conditions (see Supporting Informa-
tion S5). Although the diameter of the streptavidin-conju-
gated quantum dots is ∼20 nm in solution according to
manufacturer specifications, the AFM height measurements
of the dehydrated quantum dots correspond to the ap-
proximate diameter of the CdSe/ZnS quantum dot core/shell,
as measured by TEM (see Supporting Information S7). Thus,
with the chosen AFM imaging conditions the dehydrated
streptavidin and polymer layer contributed very little to the
measured height of the conjugated nanoparticle. The axial
profile in panel o again shows nine equally spaced peaks
with a periodicity of 49 nm.
To illustrate the flexibility of the design and confirm
control over nanoparticle attachment, functionalized DNA
nanotubes were synthesized with 5, 9, 15, and 29 biotin
attachment sites to enable the formation of quantum dot
arrays with periodicities of 71, 43, 29, and 14 nm, respec-
tively. These nanotubes were reacted with quantum dots and
dispersed onto mica substrates as in the manner described
above. Figure 2 shows high-magnification height images of
quantum dots attached to DNA nanotubes with (a) 5, (b) 9,
(c) 15, and (d) 29 biotin binding sites. Successful attachment
to each biotin binding site was observed for nanotubes with
5 or 9 available sites; however, attached quantum dots were
not observed at each site for nanotubes with 15 or 29
available sites. The average quantum dot spacings were
measured to be approximately 71( 3, 49( 4, 46( 5, and
31 ( 4 nm for nanotubes with 5, 9, 15, and 29 available
biotin binding sites, respectively. The measured spacings for
5 and 9 binding sites agree well with the predicted periods
of 71 and 43 nm. However, the arrays seen in Figure 2c,d
formed with a reduced number of quantum dots and,
FIGURE 1. Schematics, AFM images at low magnification (upper) and high magnification (lower), and cross-sectional (upper) and axial (lower)
height profiles of functionalized DNA origami nanotubes with nine biotin binding sites with (a-e) no attached nanoparticles; (f-j) attached
streptavidin; and (k-o) attached streptavidin-conjugated quantum dots. The dashed lines in the high-magnification AFM images indicate the
location of the cross-sectional profiles. Axial profiles represent the average of multiple profiles across the width of the nanotube (see Supporting
Information S6).
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consequently, a larger spacing than expected, that is, 29 and
14 nm, respectively. Additionally, successful attachment of
15 quantum dots to a DNA nanotube functionalized with 29
biotin binding sites was observed by TEM (see Supporting
Information S7). The average quantum dot spacing was
measured to be 28 ( 7 nm, in agreement with the average
spacing measured by AFM.
In Figure 2, only 10 quantum dots were attached to the
nanotube with 15 available sites, and only 17 quantum dots
were attached to the nanotube with 29 available sites. It is
also noted that for the cases of 15 and 29 binding sites, the
attached quantum dots alternate from one side of the DNA
nanotube to the other with a greater frequency than for the
cases of 5 or 9 binding sites. Several factors, hereafter
referred to as binding obstructions, that may limit quantum
dot attachment include (1) steric hindrance between quan-
tum dots, (2) quantum dots bridging multiple biotin-labeled
staple strands, (3) site poisoning of biotin-labeled staple
strands by free streptavidin, (4) biotin-labeled staple strands
that are missing their biotin modification, and (5) trapping
of tethered biotin inside the DNA nanotube. Based on the
design of the DNA nanotubes, 15 and 29 binding sites
correspond to periodicities of 29 and 14 nm, respectively.
AFM measurements of the center-to-center quantum dot
separation show a minimum separation distance of 20 nm,
which we interpret as the effective diameter of the quantum
dots in solution (see Supporting Information S8). Thus, steric
hindrance is expected for an array periodicity of 20 nm or
less (e.g., 14 nm).
To further assess the degree of successful quantum dot
attachment, Figure 3 shows histograms of the number of
quantum dots attached to DNA nanotubes labeled with (a)
5, (b) 9, (c) 15, and (d) 29 biotin binding sites. The data for
the histograms were compiled from AFM image analysis for
over 225 separate nanotubes for each case (see Supporting
Information S9). For the cases of 5 and 9 available binding
sites, the histograms are peaked at 4 and 7 successful
attachments, very near the designed number of sites. How-
ever, in the cases of 15 and 29 available sites, the histograms
are peaked at 10 and 17 successful attachments, confirming
that attachment to each available binding site is much more
likely for nanotubes functionalized with 5 or 9 binding sites
than for those with 15 or 29. It is also noted that a small
number of nanotubes appeared to have more attached
quantum dots than available binding sites, which we at-
tribute to coincidental alignment of a nanotube with full
attachment and free quantum dots.
Assuming that quantum dot binding events occur with
an equal average attachment probability for each site, the
attachment histograms would be expected to follow a
binomial distribution, P(m), given by
where n is the given number of available biotin binding sites
per nanotube andm is the number of attached quantum dots
per nanotube.52 The average attachment probability, p, is
given by
FIGURE 2. High-magnification AFM images of streptavidin-conju-
gated quantum dots attached to functionalized DNA origami nano-
tubes with (a) 5 binding sites, 71 nm period; (b) 9 binding sites, 43
nm period; (c) 15 binding sites, 29 nm period; and (d) 29 binding
sites, 14 nm period. All scale bars are 100 nm. Note (c) and (d) have
fewer attached quantum dots than available binding sites. In
addition, the diameter of quantum dots varies between images
because of variation in tip radii between scans.
FIGURE 3. Histograms (bars) and calculated binomial distributions
(lines) for the number of attached quantum dots for DNA nanotubes
with (a) 5, (b) 9, (c) 15, and (d) 29 biotin binding sites. Data for each
histogram were compiled from AFM image analysis for over 225
separate nanotubes, with the exact number, N, shown for each
histogram. The average attachment probabilities, p, used to generate
the calculated binomial distributions are indicated for each case.
P(m) ) n!
m!(n - m)!
pm(1 - p)(n-m) (1)
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where the numerator is the total number of attached quan-
tum dots, and the denominator is the total number of
available attachment sites. The average attachment prob-
abilities were calculated using eq 2 from the histogram data
to be 0.77, 0.76, 0.65, and 0.64 for 5, 9, 15, and 29 sites,
respectively. For the case of 5 binding sites, the attachment
probability for pure streptavidin was calculated from histo-
gram data to be 0.79, only slightly higher than for quantum
dot attachment (see Supporting Information S10). Similar
attachment probabilities for pure streptavidin and quantum
dots may indicate biotin-labeled staple strands are missing
their biotin modification and/or tethered biotin is trapped
inside the DNA nanotube. The solid lines in Figure 3 plot the
calculated binomial distribution of eq 1 for each case.
Overall, the calculated distributions follow the data well,
confirming equal attachment probability per site. However,
the histograms in Figure 3c,d display a slight shift toward
lower attachment, providing some evidence for steric hin-
drance or site bridging.
For evidence of steric hindrance or bridging, the nearest-
neighbor separation distances, projected along the nanotube
axis, were measured for pairs of bound quantum dots (see
Supporting Information S11). In the absence of steric hin-
drance or site bridging, the nearest-neighbor separation
histograms would be expected to follow a geometric distri-
bution peaked at the designed nanotube binding site peri-
odicity. The geometric distribution, P(l), of nearest-neighbor
separations is given by
where l is the integer number of periods between nearest-
neighbors.52 Histograms of the nearest-neighbor separations
and the geometric distributions calculated using the average
attachment probabilities p are shown in Figure 4 for each of
the four cases. For each case, measured nearest-neighbor
separation distances were normalized to represent the
number of designed binding site periods between particles.
The data were sorted into bins of width a centered on the
nth period, where a is the designed nanotube periodicity and
n is an integer. Thus, nearest-neighbor separations of less
than a/2 were indicated as a zero separation. For 5 and 9
attachment sites, the nearest-neighbor separation histo-
grams are peaked at the designed binding site periodicity.
However, for 15 and 29 binding sites, the nearest-neighbor
separation histograms are peaked at 2 and 3 periods,
respectively. The calculated geometric distributions match
the data well for the nanotubes with 5 and 9 attachment
sites, but deviate significantly for the nanotubes with 15 and
29 sites. Thus, the data may indicate that steric hindrance
or site bridging reduce the number of quantum dots attached
to the nanotubes.
Functionalized DNA origami nanotubes were designed
with biotin-labeled staple strands spaced evenly along the
axis of the nanotubes. The nanotubes were synthesized and
combined with streptavidin-conjugated quantum dots to
form nanoparticle arrays with controlled periodicities. AFM
images of the synthesized arrays revealed successful attach-
ment of quantum dots at locations along the nanotube axes
that corresponded to available biotin binding sites. Statistical
analysis of AFM images indicates that binding obstructions
establish an upper limit on the yield of nanotubes fully
occupied by quantum dots, as indicated by reduced attach-
ment probabilities and deviations from the expected nearest-
neighbor distributions for nanotubes with 15 or 29 binding
sites. In addition to steric hindrance between quantum dots
and quantum dots bridging multiple biotin-labeled staple
strands, obstructions may include (1) site poisoning of biotin-
labeled staple strands by free streptavidin, (2) biotin-labeled
staple strands that are missing their biotin modification, and
(3) trapping of tethered biotin inside the DNA nanotube. In
addition, a minimum gap distance was measured between
two streptavidin-conjugated quantum dots, thereby estab-
lishing an important design constraint when fabricating
nanoelectronic and nanoplasmonic devices based on DNA
origami.
These results provide a powerful and convenient pathway
to control nanoparticle patterning, allowing for self-as-
p )
∑ attached QD
∑ available sites (2)
P(l) ) p(1 - p)(l-1) (3)
FIGURE 4. Histograms (bars) and calculated geometric distributions
(lines) for nearest-neighbor (N-N) separation of bound quantum dot
pairs for DNA nanotubes with (a) 5, (b) 9, (c) 15, and (d) 29 biotin
binding sites. The numbers of separations,N, measured for each case
are provided in the figures, along with the average attachment
probabilities, p. N-N separation of zero indicates two nearest
neighbors with a separation less than one-half of a period.
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sembled fabrication of nanoscale electronic and photonic
devices. Because of the symmetry of DNA origami nano-
tubes and the nonrepeating sequence of the scaffold strand,
it is possible to extend the nanotube functionalization
technique to form aperiodic arrays, as well as three-
dimensional arrays. Considering there are 170 unique staple
strands that can be functionalized by various means at either
end, or even within the strand itself, the possibilities for
variations are vast. Inclusion of nanoparticles of differing size
and/or differing material is within reach and extended
networks of functionalized DNA origami nanotubes linked
together in two or even three dimensions is plausible.
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SUPPORTING INFORMATION S1: DNA Nanotube Design 
 
 
The DNA nanotubes reported here consist of six parallel double helices that are formed into a tube 
structure by combining the single-stranded M13mp18 DNA molecule with 170 staple strands using the 
DNA origami method of Rothemund.25 As shown in Fig. S1(a), the scaffold is arranged into six 
numbered helices with the ends of the M13mp18 located in the middle of helix 1. From the 5’ end, the 
scaffold proceeds to the left with crossovers at the ends of the nanotube and two staggered crossovers 
near the middle. The nucleotide numbers for the crossovers are indicated in the figure. Staple strands are 
grouped into 86 columns and numbered from the left end, as shown in Fig. S1(b). Staples are labeled 
according to the helix and column location of their 5’ end. The first column of staples starts 14 
nucleotides from the left end scaffold crossovers. Columns 11-13 show the 3 column repeating motif in 
which each staple consists of three 14 nucleotide domains complementary to a section of the M13mp18 
scaffold and spans 3 helices. Although not used in the current study, three random 20 nucleotide sticky-
ends, labeled A, B, and C, are added to staples in columns 4, 7, and 10 of helix 3. For each sticky-end, 
the helix 3 domain complementary to M13mp18 is lengthened by 7 nucleotides and the adjacent staple 
domain is correspondingly shortened, as illustrated in the figure. 
The staple strand layout in the middle of the nanotube is shown in Fig. S1(c). The 5’ and 3’ ends of 
the M13mp18 scaffold are located in helix 1 and staple column 43. Mid-nanotube scaffold crossovers 
are located in staple columns 39 and 41. The same A, B, and C sticky-ends are added to staples in 
columns 41, 45, and 48 of helix 3. Figure S1(d) illustrates the staple layout for the right end of the 
nanotube. A, B, and C sticky-ends are added to staples of columns 77, 80, and 83 of helix 3. Four 
nucleotides remain unhybridized at the end of each helix. A schematic of the formed DNA nanotube 
with A, B, and C sticky-ends is shown in Fig. S1(e). 
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FIGURE S1. Two-dimensional layout of the scaffold and staple strands of the DNA nanotube and 3D 
schematic. (a) Layout of the scaffold showing nucleotide numbers at the crossovers. (b) Staple layout 
for the left end of the tube. The staple motif is shown in columns 11-13. In helix 3, staples in columns 4, 
7, and 10 are extended with sticky-ends labeled A, B, and C. (c) Staple layout in the middle of the tube. 
The M13mp18 scaffold begins and ends in helix 1, column 43. Scaffold crossovers are located at the 
ends and in columns 39 and 41. A,B, and C sticky-ends are added to staples 41, 45, and 48 of helix 3. 
(d) Staple layout for the right end of the tube. Sticky-ends are added to staples in helix 3 in columns 77, 
80, and 83. Four nucleotides remain at the end of each helix. (e) Schematic of the formed tube 
illustrating the A, B, and C sticky-ends along helix 3 of the formed nanotube. 
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SUPPORTING INFORMATION S2: DNA Nanotube Staple Strands 
 
 
To facilitate generation of the staple strands required to form a 6-helix DNA nanotube, a Perl script 
was written to layout the scaffold sequence into the geometric raster pattern according to a given set of 
turning points. The script accepts the M13mp18 sequence as an input, divides the sequence into regions 
demarcated by turning points, and then outputs the scaffold and its complement according to the 
designed pattern. The complementary sequence is then easily divided into staple strands according to 
the desired motif. 
 
Perl Script: 
################################################################# 
#                                                               # 
#               DNA Origami Design Helper Program               # 
#                                                               # 
#                    Boise State University                     # 
#                                                               # 
################################################################# 
 
use strict; 
use warnings; 
use English; 
use Carp; 
 
exit(main());                          # a nice technique for avoiding global variables in Perl 
 
sub main { 
 
    my $DNA_SEQUENCE_FILENAME = 'M13mp18BP.txt'; 
 
    # Read the dna sequence data from the file named in $DNA_SEQUENCE_FILENAME. 
    my $DNA_SEQUENCE_FILE; 
    if (!open($DNA_SEQUENCE_FILE, "< $DNA_SEQUENCE_FILENAME")) { 
        print "Unable to open data file $DNA_SEQUENCE_FILENAME\n"; 
        return 1;                                   # failure 
    } 
    my @seqLines = <$DNA_SEQUENCE_FILE>;            # read the dna sequence data lines into  
                                                    # the seqLines array 
    close $DNA_SEQUENCE_FILE; 
    { 
        local $INPUT_RECORD_SEPARATOR = "\r\n";     # Temporarily change the record separator so that 
        chomp (@seqLines);                          # we can get rid of the line ending characters that 
                                                    # are found in text files created on Windows. 
    } 
    my $n = scalar(@seqLines); 
    print "Read $n lines from file $DNA_SEQUENCE_FILENAME.\n"; 
 
    # Convert the file data into an array of bases. 
    shift @seqLines;                                # discard the header line 
    map { $_ =~ s/[^GATC]+//g } @seqLines;          # discard everything that isn't a G, A, T, or C 
    my $dnaSequence = join '', @seqLines;           # concatenate the lines into one big string 
    print 'dnaSequence has ' . length($dnaSequence) . " bases.\n"; 
 
    # The scaffold structure is described as a set of lines and turnaround points. 
    # Data structure:  arefSubsequenceLines -> arefSubsequenceRanges -> [startPos, endPos] 
    my $arefSubsequenceLines = [ 
        [ [ 595,    1], [7249, 6637] ], 
        [ [ 596, 1162], [5996, 6636] ], 
        [ [1729, 1163], [5995, 5355] ], 
        [ [1730, 2268], [4686, 5354] ], 
        [ [2807, 2269], [4685, 4017] ], 
        [ [2808, 4016],              ], 
    ]; 
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    # Use the position data to divide the DNA sequence into the 
    # base pair sequences that make up each line of the structure. 
    my @designLines; 
    foreach my $arefSubsequenceRanges (@$arefSubsequenceLines) { 
        my $designLine = ""; 
        foreach my $arefSubsequenceRange (@$arefSubsequenceRanges) { 
            my ($p1, $p2) = @$arefSubsequenceRange;i8i8sx 
            print "p1=$p1, p2=$p2; "; 
            if ($p1 <= $p2) {           # don't need to reverse the subsequence?  
                                        # (i.e., should appear left to right?) 
                $designLine .= "*" if length($designLine) && $p1 != 1;  # separate subsequences  
                                                                        # with an asterisk 
                $designLine .= substr $dnaSequence, $p1-1, $p2-$p1+1; 
            } 
            else {                      # must reverse the subsequence because it must  
                                        # appear right to left 
                $designLine .= "*" if length($designLine) && $p2 != 1;  # separate subsequences 
                                                                        # with an asterisk 
                $designLine .= reverse substr $dnaSequence, $p2-1, $p1-$p2+1; 
            } 
            print "length(designLine)=" . length($designLine) . "\n"; 
        } 
        push @designLines, $designLine; 
        print "\n"; 
    } 
 
    my $DESIGN_OUTPUT_FILE; 
    if (!open($DESIGN_OUTPUT_FILE, "> tubedesign.txt")) { 
        print "Unable to open output file tubedesign.txt\n"; 
        return 1;                           # failure 
    } 
 
    my $COMP_DESIGN_OUTPUT_FILE; 
    if (!open($COMP_DESIGN_OUTPUT_FILE, "> comptubedesign.txt")) { 
        print "Unable to open output file comptubedesign.txt\n"; 
        return 1;                           # failure 
    } 
 
    # Format the output lines as needed for the next design step. 
    foreach my $designLine (@designLines) { 
 
        my $outputLine = $designLine; 
 
        $outputLine =~ s/([GATC]{7})\*([GATC]{7})/ $1*$2 /;     # create a 7+7 subsequence at  
                                                                # the turnaround points 
        $outputLine =~ s/([GATC]{14})/$1 /g;                    # break everything else into  
                                                                # 14-base subsequences 
        $outputLine =~ s/ {3,}/  /g;                            # make sure there are no more  
                                                                # than 2 consecutive spaces 
        $outputLine =~ s/  $//;                                 # get rid of the dangling spaces 
                                                                # at the end of the line 
 
        # Create the complements. 
        my $complementLine = $outputLine; 
        $complementLine =~ s/G/c/g; 
        $complementLine =~ s/C/g/g; 
        $complementLine =~ s/A/t/g; 
        $complementLine =~ s/T/a/g; 
        $complementLine = uc $complementLine; 
 
        print $DESIGN_OUTPUT_FILE "$outputLine\n$complementLine\n\n"; 
        print $COMP_DESIGN_OUTPUT_FILE "$complementLine\n\n"; 
    } 
 
    close $DESIGN_OUTPUT_FILE; 
    close $COMP_DESIGN_OUTPUT_FILE; 
 
    return 0;                               # success 
} 
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Table S1 provides the name and sequence for the 170 unique staple strands used for the 6-helix DNA 
nanotube reported here. The names are derived from the helix and column location of the 5’ end of the 
staple strand, as described in S1. There are 152 strands with 42 nucleotides consisting of 3 domains each 
14 nucleotides in length. Nine strands are 69 nucleotides in length, consisting of a helix-3 domain 
lengthened by 7 nucleotides plus a random 20 nucleotide sticky-end sequence. Nine strands adjacent to 
the lengthened staples are shortened by 7 nucleotides leaving 35 nucleotides.  
 
TABLE S1: Name and sequence for the 170 staple strands used for the 6-helix DNA nanotube. 
 
Helix Column Sequence 
1 2 GCCAGAGGGGGTAAAGACTCCTTATTACAACGCAAAGACACC 
1 5 CAATACTGCGGAATAACGCAATAATAACATAGAAAATTCATA 
1 8 AAATGCTTTAAACATAAGCAGATAGCCGCGACATTCAACCGA 
1 11 AAAAATCAGGTCTTAAATAGCAATAGCTAAATTATTCATTAA 
1 14 GCGGATTGCATCAACAAGAATTGAGTTAGCCATTTGGGAATT 
1 17 CAAATATCGCGTTTAGTCAGAGGGTAATTTACCATTAGCAAG 
1 20 GGAAGCAAACTCCAGAAGCGCATTAGACATAGCAGCACCGTA 
1 23 TTGCTCCTTTTGATTGAAAATAGCAGCCTTAGCGTCAGACTG 
1 26 GCTTAATTGCTGAACCCAATCCAAATAAATAGCCCCCTTATT 
1 29 ATATGCAACTAAAGGCCTAATTTGCCAGTCACCGGAACCAGA 
1 32 AACAGTTGATTCCCTTTATCCTGAATCTCCGCCACCCTCAGA 
1 35 ACCATTAGATACATCCTTAAATCAAGATGAGCCGCCACCAGA 
1 38 TATATTTTCATTTGAGGCGTTTTAGCGAACAGGAGTTAGACT 
1 41 TCTACTAATAGTAGCAAATCAGATATAGATCCTTTGCCCGAA 
1 44 GCAAGGCAAAGAATTTTATTTTCATCGTATTATCATTTTGCG 
1 47 GCATAAAGCTAAATATTAAACCAAGTACATTATCATCATATT 
1 50 TAATACTTTTGCGGATCAATAATCGGCTAATATAATCCTGAT 
1 53 AAAATTTTTAGAACAAAAATAATATCCCAGGGTTAGAACCTA 
1 56 GTAATGTGTAGGTAAGAACGCGCCTGTTAGAAATAAAGAAAT 
1 59 GACAGTCAAATCACTCTGTCCAGACGACTGAATATACAGTAA 
1 62 TGATAAATTAATGCAGTAATAAGAGAATAACGGATTCGCCTG 
1 65 TACAAAGGCTATCAAACAACGCCAACATGCGCAGAGGCGAAT 
1 68 AAGAGAATCGATGACCAACGCTCAACAGAGATGATGAAACAA 
1 71 CATATGTACCCCGGTTTAGTATCATATGTAACAATTTCATTT 
1 74 GAAGATTGTATAAGATAAGAATAAACACATAAATCAATATAT 
1 77 TTTGTTAAAATTCGTAATGGTTTGAAATCGTCGCTATTAATT 
1 80 TTTTAACCAATAGGTTTCAAATATATTTAGCGATAGCTTAGA 
1 83 CCTTCCTGTAGCCATGATGCAAATCCAAATTTATCAAAATCA 
2 2 TATCATAACCCTCGCGTCTTTCCAGACGGTACAAACTACAAC 
2 5 CATAACGCCAAAAGTTGCTAAACAACTTCCAATAGGAACCCA 
2 8 TCAGTTGAGATTTAAAGGAACAACTAAACCACCCTCAGAGCC 
2 11 AACGAACTAACGGATGAAAATCTCCAAAGGTTTAGTACCGCC 
2 14 TATACCAGTCAGGAGTATCGGTTTATCAATATAAGTATAGCC 
2 17 ATCATTGTGAATTAAGCTTGATACCGATTTTTGCTCAGTACC 
2 20 CGAGTAGTAAATTGGCCCACGCATAACCAGAGGCTGAGACTC 
2 23 TCATTCAGTGAATAGAGTTAAAGGCCGCTGCCTATTTCGGAA 
2 26 AGAACCGGATATTCAAAGACAGCATCGGGTGCCTTGAGTAAC 
2 29 GGCGCATAGGCTGGTTGAGGACTAAAGAGATGATACAGGAGT 
2 32 TGACCAACTTTGAAGGGTAAAATACGTATCTCTGAATTTACC 
2 35 GCCGGAACGAGGCGCGAAAGAGGCAAAACAAACAAATAAATC 
2 38 GATAAATTGTGTCGCCCAGCGATTATACAGAAGTAGTTGAGG 
2 41 TTTGCGTATTGGGCTCTTTTCACCAGTGTAATAGATTAGAGC 
2 44 CCAGCTGCATTAATCGCCTGGCCCTGAGTTGAGGAAGGTTAT 
2 47 GTTGCGCTCACTGCTTGCCCCAGCAGGCAATCAATATCTGGT 
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2 50 AGCCTGGGGTGCCTATCGGCAAAATCCCATCTAAAGCATCAC 
2 53 CACAATTCCACACAGGGTTGAGTGTTGTGCCTGCAACAGTGC 
2 56 ATCATGGTCATAGCAAGAACGTGGACTCAGCAGAAGATAAAA 
2 59 GTCGACTCTAGAGGCAGGGCGATGGCCCTAGCCCTAAAACAT 
2 62 CGTTGTAAAACGACTTTTTGGGGTCGAGCAATATTTTTGAAT 
2 65 AGGCGATTAAGTTGAAAGGGAGCCCCCGAGAACCCTTCTGAC 
2 68 TCTTCGCTATTACGAACGTGGCGAGAAACACACGACCAGTAA 
2 71 TTCAGGCTGCGCAAGCTAGGGCGCTGGCAATCGTCTGAAATG 
2 74 ACCGCTTCTGGTGCACCACACCCGCCGCAACAGGAAAAACGC 
2 77 GTATCGGCCTCAGGTATGGTTGCTTTGACTTGCTGGTAATAT 
2 80 GCATCGTAACCGTGAGAATCAGAGCGGGAATAACATCACTTG 
2 83 GGATTGACCGTAATTTTAGACAGGAACGATCACGCAAATTAA 
3 1 ATCTAAAGTTTTGTTTTACCAGACGACGGCAAAAGAAGTTTT 
3 4 GAACGCACTTGGTCTACTGAATGAATTTTCTGTATGGGATTGAATTACGAGGCATGACTGGATAGCGTC 
3 7 GTGACATACCTTCGGAGCATTTTCAGCGGAGTGAGAATAGAGGAATACCACATTCATTGAATCCCCCTC 
3 10 CGCTTCACGAGGTTACAATGCGAATAATAATTTTTTCACGTACAACATTATTACAAATGACCATAAATC 
3 13 AGGAGCCTTTAATTCGTTGGGAAGAAAATAGTCAGAAGCAAA 
3 16 TGAATTTCTTAAACCCTTATGCGATTTTAGCCCGAAAGACTT 
3 19 TGACAACAACCATCGGCTTGAGATGGTTAAGCGAACCAGACC 
3 22 CTGAGGCTTGCAGGAGGCTTGCCCTGACGAGAGTACCTTTAA 
3 25 CACCCTCAGCAGCGATTACCCAAATCAAGCGGATGGCTTAGA 
3 28 CGGCTACAGAGGCTCTGACCTTCATCAATCAACATGTTTTAA 
3 31 AGTTTCCATTAAACAGAGGACAGATGAAGTTTCATTCCATAT 
3 34 GCACCAACCTAAAACAGACGGTCAATCAGTAGATTTAGTTTG 
3 37 ACTCATCTTTGACCAAATCCGCGACCTGATAACCTGTTTAGC 
3 40 GAACGCACTTGGTCTACTGAGAAACAAAGTACAATGGTTTTGCCAGGGCGGAGATAAGGTGGCATCAAT 
3 43 GTGACATACCTTCGGAGCATCAACAGCTGATTGCCCTTCACGAATCGGCCAACGCAATAAATCATACAG 
3 46 CGCTTCACGAGGTTACAATGCAGCAAGCGGTCCACGCTGGTCCGCTTTCCAGTCGAATAAAGCCTCAGA 
3 49 ATGGTGGTTCCGAAAATGAGTGAGCTAAACATTATGACCCTG 
3 52 AATAGCCCGAGATAACATACGAGCCGGATCAACGCAAGGATA 
3 55 AGAGTCCACTATTATGTTTCCTGTGTGAAATGCAATGCCTGA 
3 58 GAAAAACCGTCTATATCCCCGGGTACCGTGAGAAAGGCCGGA 
3 61 CACCCAAATCAAGTGGCCAGTGCCAAGCTCAACCGTTCTAGC 
3 64 TAAATCGGAACCCTGGTAACGCCAGGGTATTTTTGAGAGATC 
3 67 GGGGAAAGCCGGCGCCAGCTGGCGAAAGAGTCTGGAGCAAAC 
3 70 CGAAAGGAGCGGGCCTGTTGGGAAGGGCACTAGCATGTCAAT 
3 73 CGCTGCGCGTAACCCGGAAACCAGGCAAAGCCCCAAAAACAG 
3 76 GAACGCACTTGGTCTACTGAGCGCCGCTACAGGGCGCGTACAAGATCGCACTCCAGTAAACGTTAATAT 
3 79 GTGACATACCTTCGGAGCATGTATAACGTGCTTTCCTCGTTCATCTGCCAGTTTGTAAATCAGCTCATT 
3 82 CGCTTCACGAGGTTACAATGCAGGAGGCCGATTAAAGGGATGGGATAGGTCACGTTAATTCGCGTCTGG 
3 85 TGAGAAGTGTTTTTCGTCGGATTCTCCGTAAATGTGAGCGAG 
4 1 GCCTGTAGCATTCCCAACATATAAAAGAGCAGTATGTTAGCA 
4 4 TGTACCGTAACACTTTTTGTCACAATCAGGAATACCCAAAAG 
4 7 ACCACCCTCATTTTCAAAGACAAAAGGGAACAAAGTTACCAG 
4 10 ACCCTCAGAACCGCGTAAATATTGACGGATCTTACCGAAGCC 
4 13 CGGAATAGGTGTATCGTCACCGACTTGAAGCCCAATAATAAG 
4 16 AGGCGGATAAGTGCCACCAGTAGCACCATGAGCGCTAATATC 
4 19 CTCAAGAGAAGGATCAATGAAACCATCGGGGAGAATTAACTG 
4 22 CCTATTATTCTGAAAATCAAGTTTGCCTTTTACAGAGAGAAT 
4 25 AGTGCCCGTATAAACGGCATTTTCGGTCGAAACGATTTTTTG 
4 28 GTACTGGTAATAAGTTTCATAATCAAAATTACAAAATAAACA 
4 31 GTTCCAGTAAGCGTCGCCTCCCTCAGAGTACCAACGCTAACG 
4 34 CTCATTAAAGCCAGAGCCACCACCCTCATAGTTGCTATTTTG 
4 37 CAGGTCAGACGATTCGCCGCCAGCATTGACCTCCCGACTTGC 
4 40 CGTCAATAGATAATACAACTCGTATTAAAAGGCTTATCCGGT 
4 43 CTAAAATATCTTTAAAAGTTTGAGTAACAGGAATCATTACCG 
4 46 CAGTTGGCAAATCACCAGAAGGAGCGGACGCACTCATCGAGA 
4 49 CTTGCTGAACCTCAGATGGCAATTCATCGTCTTTCCTTATCA 
4 52 CACGCTGAGAGCCATTCTGAATAATGGAATCCTAATTTACGA 
4 55 CAGAGGTGAGGCGGTTTGCACGTAAAACTATCAACAATAGAT 
4 58 CGCCATTAAAAATAGGTTTAACGTCAGAGACAATAAACAACA 
4 61 GGCTATTAGTCTTTTCGGGAGAAACAATATAAAGTACCGACA 
4 64 CTGAAAGCGTAAGACAAGTTACAAAATCGTAATTTAGGCAGA 
4 67 TAAAAGGGACATTCACCTGAGCAAAAGATAGGGCTTAATTGA 
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4 70 GATTATTTACATTGAAATTAATTACATTCGTTATACAAATTC 
4 73 TCATGGAAATACCTAATGGAAACAGTACCGGAATCATAATTA 
4 76 CCAGAACAATATTATTGCTTCTGTAAATACCGACCGTGTGAT 
4 79 CCTGAGTAGAAGAAATCCTTGAAAACATTAGTTAATTTCATC 
4 82 CCGTTGTAGCAATAAGAGTCAATAGTGATCGCAAGACAAAGA 
4 85 TGAGGCCACCGAGTTACCTTTTTAACCTGTTGGGTTATATAA 
5 3 ACGGAATAAGTTTAGAGTTTCGTCACCATTAGTAA 
5 6 TGGTTTACCAGCGCCAGGGATAGCAAGCTCAACAG 
5 9 TTGAGGGAGGGAAGCACCCTCAGAACCGGGAATTG 
5 12 AGGTGAATTATCACCACCGTACTCAGGAAAAAAGGCTCCAAA 
5 15 AGAGCCAGCAAAATCGTCGAGAGGGTTGGCTTGCTTTCGAGG 
5 18 GCCGGAAACGTCACTAGGATTAGCGGGGAGTTGCGCCGACAA 
5 21 ATCAGTAGCGACAGACATGAAAGTATTAGATATATTCGGTCG 
5 24 TAGCGCGTTTTCATCAGTTAATGCCCCCTTTTGCGGGATCGT 
5 27 AGCGTTTGCCATCTTTTTAACGGGGTCAAACGAGGGTAGCAA 
5 30 GCCACCACCGGAACCATACATGGCTTTTCTTTTTCATGAGGA 
5 33 ACCGCCACCCTCAGAATGGAAAGCGCAGATGCCACTACGAAG 
5 36 ACCACCACCAGAGCGGCCTTGATATTCAGAATACACTAAAAC 
5 39 TTACAAACAATTCGACATTTGAGGATTTCAAGCGC 
5 42 CGTTATTAATTTTAGGAGCACTAACAACAGACGGG 
5 45 GAACAAAGAAACCAACAGTTGAAAGGAAAGAGTTG 
5 48 CCTGATTATCAGATAATATCAAACCCTCGAAAATCCTGTTTG 
5 51 TGTTTGGATTATACGCAGCAAATGAAAATTATAAATCAAAAG 
5 54 CCATATCAAAATTATCAGTATTAACACCTCCAGTTTGGAACA 
5 57 TGCGTAGATTTTCACCGAACGAACCACCCAACGTCAAAGGGC 
5 60 CAGTACCTTTTACAAATGCGCGAACTGAACTACGTGAACCAT 
5 63 ATTGCTTTGAATACATACGTGGCACAGAGTGCCGTAAAGCAC 
5 66 TATTCATTTCAATTTGGCCAACAGAGATATTTAGAGCTTGAC 
5 69 ACATCAAGAAAACAGCAGATTCACCAGTGGAAGGGAAGAAAG 
5 72 GAATTACCTTTTTTACATTTTGACGCTCAAGTGTAGCGGTCA 
5 75 GTGAGTGAATAACCCCGCCAGCCATTGCGCTTAAT 
5 78 AATTTTCCCTTAGACTCAAACTATCGGCCGAGCAC 
5 81 TTAAGACGCTGAGACTTCTTTGATTAGTAGCTAAA 
5 84 TAGGTCTGAGAGACAAAAGAGTCTGTCCGTACGCCAGAATCC 
6 3 AACTGGCATGATTATAGTAAAATGTTTAAGTAAGAGCAACAC 
6 6 AAGGAAACCGAGGACGTCATAAATATTCAACTAATGCAGATA 
6 9 CTTTTTAAGAAAAGGTTCAGAAAACGAGGGTAGAAAGATTCA 
6 12 AGCAAGAAACAATGTACCCTGACTATTAATCTACGTTAATAA 
6 15 AGAGAGATAACCCAAAAGATTAAGAGGAAAGAACTGGCTCAT 
6 18 AACACCCTGAACAATAATTCGAGCTTCATAATTTCAACTTTA 
6 21 AACATAAAAACAGGACAGGTCAGGATTAGAGAAACACCAGAA 
6 24 TTTAACGTCAAAAAAAGAGGTCATTTTTCGTAACAAAGCTGC 
6 27 GCCATATTATTTATTATAATGCTGTAGCGAGTAATCTTGACA 
6 30 AGCGTCTTTCCAGATACGGTGTCTGGAACGGTGTACAGACCA 
6 33 CACCCAGCTACAATAATTCTGCGAACGATAAGGGAACCGAAC 
6 36 GGGAGGTTTTGAAGTTCGCAAATGGTCACTCCATGTTACTTA 
6 39 ATTCTAAGAACGCGGGGCGCGAGCTGAATTGTATCATCGCCT 
6 42 CGCCCAATAGCAAGTAGCATTAACATCCGCGGGGAGAGGCGG 
6 45 ACAAGCAAGCCGTTTAGCAAAATTAAGCGGAAACCTGTCGTG 
6 48 TTCCAAGAACGGGTCGGTTGTACCAAAACTCACATTAATTGC 
6 51 GCATGTAGAAACCAGAGAAGCCTTTATTAGCATAAAGTGTAA 
6 54 AAGTCCTGAACAAGCCTCATATATTTTAAATTGTTATCCGCT 
6 57 TGTTCAGCTAATGCAAGATTCAAAAGGGAGCTCGAATTCGTA 
6 60 AAAGGTAAAGTAATCATCAATATGATATTTGCATGCCTGCAG 
6 63 GGCATTTTCGAGCCCGGAGAGGGTAGCTTTTCCCAGTCACGA 
6 66 GAATCGCCATATTTGGTCATTGCCTGAGGGGGATGTGCTGCA 
6 69 TTACCAGTATAAAGACGGTAATCGTAAAGATCGGTGCGGGCC 
6 72 CTAGAAAAAGCCTGTTGATAATCAGAAAAGCGCCATTCGCCA 
6 75 AAATAAGGCGTTAACAAATATTTAAATTGCCAGCTTTCCGGC 
6 78 TTCTGACCTAAATTCATTAAATTTTTGTAGGGGACGACGACA 
6 81 ACGCGAGAAAACTTAACGCCATCAAAAATGGTGTAGATGGGC 
6 84 CTATATGTAAATGCGCTTTCATCAACATTGGGAACAAACGGC 
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SUPPORTING INFORMATION S3: Modified Staple Strands 
 
 
To form functionalized DNA nanotubes with 29 attachment sites for streptavidin-conjugated 
nanoparticles, all 29 staple strands of helix 4 (H4-C1 to H4-C85) were modified by adding a 5 thymine 
tether to the 3’ end followed by a biotin molecule. During synthesis of the nanotubes, these strands were 
substituted for the corresponding unmodified staple strands. Note that the strands are labeled in helix 4 
by the location of their 5’ end, but the biotin modified 3’ ends are located in helix 6. To synthesize 
nanotubes with 15, 9 and 5 available binding sites, the subsets of the helix 4 staple strands were 
substituted. The column numbers of the substituted staple strands are listed below. 
 
For 15 binding sites, every other staple of helix 4 was substituted:  
1, 7, 13, 19, 25, 31, 37, 43, 49, 55, 61, 67, 73, 79, 85. 
 
For 9 binding sites, every third staple of helix 4 was substituted, starting with column 7:  
7, 16, 25, 34, 43, 52, 61, 70, 79. 
 
For 5 binding sites, every fifth staple of helix 4 was substituted, starting with column 5:  
13, 28, 43, 58, 73. 
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SUPPORTING INFORMATION S4: AFM Calibration 
 
 
To validate the linearity, stability, and accuracy of the piezoelectric scanners, the AFM was calibrated 
using: 1) a surface topography reference (STR3-1800P, VLSI Standards), and 2) the atomic step height 
of freshly cleaved, ZYH grade, highly ordered pyrolytic graphite (HOPG, Veeco Metrology). The STR 
was lithographically fabricated onto a silicon dioxide on silicon die (Model # STR3-1800P) and 
contained an array of alternating silicon dioxide bars. With a pitch distance of 3 µm in both the X and Y 
directions, the bars formed 180 nm deep rectangular pits. Following Veeco Metrology guidelines, the 
AFM Z-axis piezoelectric stack was calibrated for neutral (0 V ± 5 V), extended (50 V ± 5 V), and 
retracted (-50 V ± 5 V) conditions. As shown in Table S2, a mean step height of 180.4 ± 0.4 nm was 
measured at 0 V ± 5 V and is well within the 1-2% accuracy specified by the manufacturer. To verify 
the calibration of the AFM at small length scales, the mean atomic step height of freshly cleaved, ZYH 
grade, HOPG was measured to be 0.35 nm with a standard deviation of 0.01 nm. Both the tabulated data 
and an example height image of the graphite step height are shown in Table S3 and Figure S2, 
respectively. When compared to the accepted 0.34 nm step height of HOPG, the AFM was properly 
calibrated.* 
 
TABLE S2: Calibration of the AFM using a Surface Topography Reference. 
 
Step Height of Surface 
Topography Reference  
Expected 
Value (nm) 
Measured 
Value (nm) 
Relative 
Error (%) 
Neutral Position (0V ± 5V) 180 180.4 0.2 
Extended Offset (50V ± 5V) 180 181.6 0.9 
Retracted Offset (-50V ± 5V) 180 181.3 0.7 
 
 
 
 
 
 
* L. Pauling, The Nature of the Chemical Bond, p. 235, 3rd. Edition 1960.  
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TABLE S3: Calibration of the AFM using freshly cleaved, highly ordered pyrolytic graphite (HOPG). 
 
Number of HOPG Steps  Expected Value (nm) 
Measured 
Value (nm) 
Relative 
Error (%) 
1 0.34 0.36 4.7 
2 0.34 0.34 0.3 
3 0.34 0.33 2.4 
4 0.34 0.34 0.6 
5 0.34 0.35 3.5 
6 0.34 0.35 2.1 
7 0.34 0.38 10.9 
8 0.34 0.35 1.8 
9 0.34 0.34 0.6 
10 0.34 0.33 2.1 
11 0.34 0.35 2.4 
12 0.34 0.34 0.0 
13 0.34 0.33 1.8 
14 0.34 0.34 0.3 
15 0.34 0.34 0.3 
16 0.34 0.33 2.4 
17 0.34 0.35 3.8 
18 0.34 0.37 7.9 
 
 
                         
FIGURE S2. AFM height image of an atomic step on HOPG used for calibration.  The profile 
averaging box corresponds to the inset height profile. 
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SUPPORTING INFORMATION S5: AFM Height Profiles 
 
 
According to X-ray analysis, dehydrated streptavidin crystals are 4.6 nm thick.48-51 In comparison, 
hydrated self-assembled monolayers (SAMs) of biotin-bound streptavidin are ~4.5 nm using Mach-
Zehnder interferometry and surface plasmon techniques.51 Although nearly identical, optical techniques 
often underestimate monolayer thickness by assuming a refractive index of n = 1.45 for streptavidin in 
air and solvent.51 With waveguide mode spectroscopy, Busse et al., independently measured the index 
of refraction and the geometric thickness of phosphate buffered saline (PBS) hydrated streptavidin to be 
1.42 and 8 nm, respectively.51 Adopting these values, the experimental film thickness was ~6 nm.51 To 
mitigate discrepancy between optical techniques, AFM was also performed in PBS solution.51 AFM 
height data indicated that streptavidin formed a closed packed film with a sphere diameter and 
monolayer height of 10 nm and ~6 nm, respectively. Although comparable to waveguide mode 
spectroscopy, an increase in the normal stylus force during AFM imaging is known to cause a 
measurable decrease in the height profile of soft biological samples.41 
Reduced AFM height profiles for soft biological samples have been corroborated by multiple studies. 
41, 46-47 According to the theoretical calculations by Persson, globular proteins, such as streptavidin, will 
deform for forces >10 pN.45 Experimentally, Weisenhorn et al. imaged streptavidin under different 
AFM contact forces and demonstrated that the maximum height varied between 1.12, 0.65, and 0.25 nm 
at 30, 60, and 150 pN, respectively.44 As a consequence, the compressibility of streptavidin, in the 
vertical direction, was approximated to be 0.2 nm/MPa.44 
Within this study, the mean height of free streptavidin dispersed onto freshly-cleaved mica was 
measured under various imaging conditions. In Fig. S3, the AFM free air drive amplitude and setpoint 
were modulated between 0.5 V (setpoint = 0.35V) and 2 V (setpoint = 1.75V) for a similar scan area.  
During sequential images under these conditions, the mean height for 10 streptavidin molecules 
alternated between (a) 1.3 ± 0.3 nm, (b) 0.5 ± 0.2 nm, and (c) 1.3 ± 0.3 nm, respectively. Elastic 
recovery of the mean streptavidin height indicates the lack of significant sample degradation. 
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FIGURE S3. AFM images of free streptavidin dispersed onto freshly-cleaved mica. The images were 
acquired in succession with drive amplitudes and setpoints of (a) 0.5 V and 0.35 V, (b) 2 V and 1.75 V, 
and (c) 0.5 V and 0.35 V, respectively. 
 
Further characterization of height variations under different AFM imaging conditions is provided in 
Fig. S4 for (a-d) bare nanotubes, (e-h) free streptavidin, and (i-l) free streptavidin-conjugated quantum 
dots on freshly cleaved mica. Images of the same sample area were obtained with free air drive 
amplitudes of 0.5 V and 2 V using setpoints at ~90% and ~50% of the drive amplitude, as shown in the 
traces provided below each image. The red, blue, and green traces in Fig. S4 represent the Z-piezo 
extending towards the surface, retracting from the surface, and setpoint, respectively. The mean heights 
of the features indicated by arrows are provided in the images, confirming apparent height variations 
under different imaging conditions.  Both the nanotubes and streptavidin show decreasing heights for 
increased imaging forces, while the quantum dot heights are roughly constant. These results are 
consistent with what one would expect for AFM imaging of soft and hard materials. 
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FIGURE S4.  AFM height images obtained under soft and hard imaging conditions for (a-d) bare 
nanotubes, (e-h) free streptavidin, and (i-l) free streptavidin-conjugated quantum dots on mica. Images 
of the same sample area were obtained with free air drive amplitudes of 0.5 V and 2 V using setpoints at 
~90% and ~50% of the free air drive amplitude, as shown in the traces provided above each image.  The 
mean heights of the features are provided in each AFM height image.
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SUPPORTING INFORMATION S6: AFM Axial Profiles 
 
Axial profiles of DNA nanotubes were obtained using a box profile tool that averages height data 
perpendicular to the box axis. This method provides smoother height features, but absolute height 
information is lost by averaging.  Figure S5 illustrates use of the box profile tool along the axis of 
functionalized DNA nanotubes with 9 available biotin binding sites. The nanotube measured in Fig. 
S5(a) shows 9 attached streptavidin molecules and the nanotube in Fig. S5(c) shows 9 attached 
streptavidin-conjugated quantum dots. The resulting profiles shown in Figs. S5(b) and (d) clearly 
indicate the attached particles. The reduced height scales of the resulting profiles illustrate the effects of 
averaging. 
     
 
FIGURE S5. AFM height images of DNA origami nanotubes functionalized with 9 biotin binding sites 
showing (a) attached streptavidin and (c) attached streptavidin-conjugated quantum dots. (b) and (d) 
show the resulting axial profiles. 
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SUPPORTING INFORMATION S7: TEM of Streptavidin-Conjugated Quantum Dots 
 
Transmission electron microscopy (TEM) was used to confirm the average diameter of the CdSe/ZnS 
core/shell quantum dots in the streptavidin-conjugated nanoparticles, as shown in Fig. S6. TEM images 
were obtained using a JEOL JEM-2100 HR Analytical Transmission Electron Microscope operating at 
200 keV. The conjugated nanoparticles were dispersed onto an amorphous carbon coated TEM grid for 
imaging. The image contrast was insufficient for observing the polymer or streptavidin layers of the 
conjugates. Image analysis yielded an average quantum dot diameter of 5.3 ± 0.9 nm. 
 
 
FIGURE S6. TEM image of streptavidin-conjugated quantum dots supported on an amorphous carbon 
thin film. 
 
Successful attachment of quantum dots was confirmed with TEM imaging of DNA nanotubes 
functionalized with 29 biotin binding sites. Unstained DNA nanotubes with attached quantum dots were 
dispersed onto a 2 nm thick carbon film supported by a holey carbon film on a copper TEM grid. 
Images of the sample were acquired at 120 keV. The image shown in Fig. S7 reveals an array of 15 
quantum dots formed along the length of a DNA nanotube. The average spacing of the quantum dots 
was 28 ± 7 nm, which agrees with the average spacing measured by AFM for nanotubes with 29 binding 
sites. 
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FIGURE S7. TEM image of a 15 quantum dot array formed by successful attachment to a DNA 
nanotube functionalized with 29 biotin binding sites. The average quantum dot spacing was 28 ± 7 nm, 
which agrees with the average spacing measured by AFM. The DNA nanotube was not stained, and the 
image was acquired at 120 keV. 
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SUPPORTING INFORMATION S8: Center-to-Center Separation of Streptavidin-Conjugated QDs 
 
 
For each design periodicity, AFM images of DNA nanotubes with attached quantum dots were 
analyzed to measure the center-to-center separation distances between nearest-neighbor quantum dots. 
Histograms of the measured separations are shown in Fig. S8. In each case, no quantum dots were 
observed with a center-to-center separation less than 20 nm. Thus, the data indicate that in solution, the 
effective diameter of the streptavidin-conjugated quantum dots is 20 nm, in agreement with the 
specifications provided by Invitrogen. 
 
 
 
FIGURE S8. Center-to-center distance between nearest-neighbor streptavidin-conjugated quantum dots 
attached to DNA origami nanotubes with (a) 5, (b) 9, (c) 15, and (d) 29 biotin binding sites. 
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SUPPORTING INFORMATION S9: Quantum Dot Counting Methodology 
 
 
To generate histograms of the numbers of attached quantum dots per DNA nanotube, large area AFM 
images of DNA nanotubes with attached quantum dots were analyzed for each designed attachment 
periodicity. The example AFM images in Fig. S9(a-d) illustrates the methodology used in classifying a 
quantum dot as attached to a DNA nanotube. Regions in which multiple nanotubes contacted each other 
were excluded from statistical analysis (e.g., “X” region in Fig. S9(d)). In Figs. S9(c) and (d), counted 
quantum dots are indicated with a circled dot. Quantum dots that appeared close to but separated from a 
nanotube were not counted. 
 
 
FIGURE S9. AFM height images of DNA nanotubes functionalized with (a) 9 and (b) 29 biotin sites 
and attached quantum dots. Images (c) and (d) illustrate counted quantum dots, while image (d) also 
illustrates excluded nanotubes. Counted quantum dots are marked with a circled dot.
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SUPPORTING INFORMATION S10: Attachment of Pure Streptavidin 
 
For the case of 5 available binding sites, AFM images of functionalized DNA nanotubes with attached 
pure streptavidin were analyzed to determine the number of attached molecules per nanotube. Figure 
S10(a) shows a histogram of the number of attached streptavidin molecules per DNA nanotube. For 
comparison, a histogram of the number of attached quantum dots is shown in Fig. S10(b), also for 5 
available binding sites. Although the attachment histogram of streptavidin is peaked for 5 attached 
molecules per DNA nanotube, the average attachment probability of 0.79 for pure streptavidin 
attachment was calculated from Equation 2 and is only slightly higher than for quantum dot attachment. 
Thus, for the cases of large separations between attachment sites (no steric hindrance), the attachment 
probabilities for streptavidin and quantum dots may reflect missing or unavailable biotin sites. 
 
 
 
FIGURE S10. Histogram (bars) and calculated binomial distributions (lines) for the number of attached 
(a) pure streptavidin, and (b) quantum dots for DNA nanotubes functionalized with 5 biotin binding 
sites. Data for each histogram were compiled from AFM image analysis for over 100 separate 
nanotubes, with the exact number, N, shown in each histogram. The average attachment probabilities 
used to generate the binomial distributions are indicated for each case. 
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SUPPORTING INFORMATION S11: Projected Nearest-Neighbor Quantum Dot Separations 
 
 
For direct evidence of steric hindrance or site poisoning, AFM images were analyzed to determine 
nearest-neighbor separation distances projected along the axis of the DNA nanotubes. The AFM images 
shown in Fig. S11 illustrate the measurement process. To facilitate accurate measurements, long white 
guide lines are drawn through the center of the quantum dots and perpendicular to the nanotube tangent. 
The projected separation is measured as the distance between the intersections of the guide lines and the 
nanotube axis tangents. For nanotubes with significant curvature between quantum dots, multiple axial 
measurements were combined, as illustrated in Fig. S11(d). 
 
 
 
FIGURE S11. AFM images showing measurement of nearest-neighbor quantum dot separations 
projected along the axis of the DNA nanotube. Images (a) and (b) show the projected separation for two 
neighboring quantum dots whose center-to-center distances are larger than the projected separations. 
Image (c) and (d) show projected separation measurements for quantum dots along curved sections of 
the DNA nanotubes. 
